Cargando…

A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells

The most common aortic valve diseases in adults are stenosis due to calcification and regurgitation. In pediatric patients, aortic pathologies are less common. When a native valve is surgically replaced by a prosthetic one, it is necessary to consider that the latter has a limited durability. In par...

Descripción completa

Detalles Bibliográficos
Autores principales: Faggioli, Marika, Moro, Arianna, Butt, Salman, Todesco, Martina, Sandrin, Deborah, Borile, Giulia, Bagno, Andrea, Fabozzo, Assunta, Romanato, Filippo, Marchesan, Massimo, Imran, Saima, Gerosa, Gino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949722/
https://www.ncbi.nlm.nih.gov/pubmed/35335556
http://dx.doi.org/10.3390/polym14061226
_version_ 1784674972607709184
author Faggioli, Marika
Moro, Arianna
Butt, Salman
Todesco, Martina
Sandrin, Deborah
Borile, Giulia
Bagno, Andrea
Fabozzo, Assunta
Romanato, Filippo
Marchesan, Massimo
Imran, Saima
Gerosa, Gino
author_facet Faggioli, Marika
Moro, Arianna
Butt, Salman
Todesco, Martina
Sandrin, Deborah
Borile, Giulia
Bagno, Andrea
Fabozzo, Assunta
Romanato, Filippo
Marchesan, Massimo
Imran, Saima
Gerosa, Gino
author_sort Faggioli, Marika
collection PubMed
description The most common aortic valve diseases in adults are stenosis due to calcification and regurgitation. In pediatric patients, aortic pathologies are less common. When a native valve is surgically replaced by a prosthetic one, it is necessary to consider that the latter has a limited durability. In particular, current bioprosthetic valves have to be replaced after approximately 10 years; mechanical prostheses are more durable but require the administration of permanent anticoagulant therapy. With regard to pediatric patients, both mechanical and biological prosthetic valves have to be replaced due to their inability to follow patients’ growth. An alternative surgical substitute can be represented by the acellular porcine aortic valve that exhibits less immunogenic risk and a longer lifespan. In the present study, an efficient protocol for the removal of cells by using detergents, enzyme inhibitors, and hyper- and hypotonic shocks is reported. A new detergent (Tergitol) was applied to replace TX-100 with the aim to reduce toxicity and maximize ECM preservation. The structural integrity and efficient removal of cells and nuclear components were assessed by means of histology, immunofluorescence, and protein quantification; biomechanical properties were also checked by tensile tests. After decellularization, the acellular scaffold was sterilized with a standard protocol and repopulated with bone marrow mesenchymal stem cells to analyze its biocompatibility profile.
format Online
Article
Text
id pubmed-8949722
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89497222022-03-26 A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells Faggioli, Marika Moro, Arianna Butt, Salman Todesco, Martina Sandrin, Deborah Borile, Giulia Bagno, Andrea Fabozzo, Assunta Romanato, Filippo Marchesan, Massimo Imran, Saima Gerosa, Gino Polymers (Basel) Article The most common aortic valve diseases in adults are stenosis due to calcification and regurgitation. In pediatric patients, aortic pathologies are less common. When a native valve is surgically replaced by a prosthetic one, it is necessary to consider that the latter has a limited durability. In particular, current bioprosthetic valves have to be replaced after approximately 10 years; mechanical prostheses are more durable but require the administration of permanent anticoagulant therapy. With regard to pediatric patients, both mechanical and biological prosthetic valves have to be replaced due to their inability to follow patients’ growth. An alternative surgical substitute can be represented by the acellular porcine aortic valve that exhibits less immunogenic risk and a longer lifespan. In the present study, an efficient protocol for the removal of cells by using detergents, enzyme inhibitors, and hyper- and hypotonic shocks is reported. A new detergent (Tergitol) was applied to replace TX-100 with the aim to reduce toxicity and maximize ECM preservation. The structural integrity and efficient removal of cells and nuclear components were assessed by means of histology, immunofluorescence, and protein quantification; biomechanical properties were also checked by tensile tests. After decellularization, the acellular scaffold was sterilized with a standard protocol and repopulated with bone marrow mesenchymal stem cells to analyze its biocompatibility profile. MDPI 2022-03-17 /pmc/articles/PMC8949722/ /pubmed/35335556 http://dx.doi.org/10.3390/polym14061226 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Faggioli, Marika
Moro, Arianna
Butt, Salman
Todesco, Martina
Sandrin, Deborah
Borile, Giulia
Bagno, Andrea
Fabozzo, Assunta
Romanato, Filippo
Marchesan, Massimo
Imran, Saima
Gerosa, Gino
A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
title A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
title_full A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
title_fullStr A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
title_full_unstemmed A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
title_short A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
title_sort new decellularization protocol of porcine aortic valves using tergitol to characterize the scaffold with the biocompatibility profile using human bone marrow mesenchymal stem cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949722/
https://www.ncbi.nlm.nih.gov/pubmed/35335556
http://dx.doi.org/10.3390/polym14061226
work_keys_str_mv AT faggiolimarika anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT moroarianna anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT buttsalman anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT todescomartina anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT sandrindeborah anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT borilegiulia anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT bagnoandrea anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT fabozzoassunta anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT romanatofilippo anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT marchesanmassimo anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT imransaima anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT gerosagino anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT faggiolimarika newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT moroarianna newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT buttsalman newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT todescomartina newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT sandrindeborah newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT borilegiulia newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT bagnoandrea newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT fabozzoassunta newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT romanatofilippo newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT marchesanmassimo newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT imransaima newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells
AT gerosagino newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells